Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

INVEGA HAFYERA® (paliperidone palmitate 6-month)

Medical Information

+ Save link

Use of INVEGA HAFYERA in Patients with Comorbid Substance Abuse

Last Updated: 10/01/2024

Summary

INVEGA HAFYERA has not been studied in patients with comorbid substance abuse.
- A diagnosis of moderate or severe substance use disorder (except for nicotine and caffeine) within 6 months of screening was an exclusion criterion in the pivotal INVEGA HAFYERA trial.¹
- Patients in the study were strongly encouraged not to use alcohol, illicit substances, or recreational marijuana during the study. Medical marijuana was strictly prohibited.²

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, DERWENTDrug File(and/or other resources, including internal/external databases) pertaining to this topic was conducted on 13 September 2024.

References

Show

1	Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238-251.
2	Data on File. Protocol R092670PSY3015, Version 005. Janssen Research & Development, LLC; 2019.